![]() ![]() Results At inclusion the women on average were aged 50 and had been postmenopausal for seven months. Main outcome measure The primary endpoint was a composite of death, admission to hospital for heart failure, and myocardial infarction. ![]() Sensitivity analyses were carried out on women who took more than 80% of the prescribed treatment for five years. Intervention was stopped after about 11 years owing to adverse reports from other trials, but participants were followed for death, cardiovascular disease, and cancer for up to 16 years. ![]() Interventions In the treatment group, women with an intact uterus were treated with triphasic estradiol and norethisterone acetate and women who had undergone hysterectomy received 2 mg estradiol a day. Women who had undergone hysterectomy were included if they were aged 45-52 and had recorded values for postmenopausal serum follicle stimulating hormone. 502 women were randomly allocated to receive hormone replacement therapy and 504 to receive no treatment (control). Participants 1006 healthy women aged 45-58 who were recently postmenopausal or had perimenopausal symptoms in combination with recorded postmenopausal serum follicle stimulating hormone values. Objective To investigate the long term effect of hormone replacement therapy on cardiovascular outcomes in recently postmenopausal women.ĭesign Open label, randomised controlled trial. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |